A phase 3, single-arm, open-label study to evaluate the safety, tolerability, and immunogenicity of a 15-valent pneumococcal conjugate vaccine, V114, in a 3+1 regimen in healthy infants in South Korea (PNEU-PED-KOR)

References

• Kim GR, Kim EY, Kim SH, Lee HK, Lee J, Shin JH, Kim YR, Song SA, Jeong J, Uh Y, et al. Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae causing invasive pneumococcal disease in Korea between 2017 and 2019 after introduction of the 13-valent pneumococcal conjugate vaccine. Ann Lab Med. 2023;43(1):45–7. doi:10.3343/alm.2023.43.1.45.
   PubMed Web of Science ®Google Scholar
• Grant LR, Slack MPE, Theilacker C, Vojicic J, Dion S, Reinert R-R, Jodar L, Gessner BD. Distribution of serotypes causing invasive pneumococcal disease in children from high-income countries and the impact of pediatric pneumococcal vaccination. Clin Infect Dis. 2023;76:1062–70. doi:10.1093/cid/ciac475.
   Web of Science ®Google Scholar
• Center for Disease Control and Prevention. Pneumococcal disease. 2022 [accessed 2023 Jun 1]. https://www.cdc.gov/pneumococcal/clinicians/streptococcus-pneumoniae.html.
   Google Scholar
• Jimbo Sotomayor R, Toscano CM, Sanchez Choez X, Vilema Ortíz M, Rivas Condo J, Ghisays G, Haneuse S, Weinberger DM, McGee G, de Oliveira LH, et al. Impact of pneumococcal conjugate vaccine on pneumonia hospitalization and mortality in children and elderly in Ecuador: time series analyses. Vaccine. 2020;38:7033–9. doi:10.1016/j.vaccine.2020.09.032.
   PubMed Web of Science ®Google Scholar
• Mohanty S, Podmore B, Moral AC, Matthews I, Sarpong E, Lacetera A, Qizilbash N. Incidence of pneumococcal disease from 2003 to 2019 in children ≤17 years in England. Pneumonia. 2023;15:1–11. doi:10.1186/s41479-022-00103-3.
   Web of Science ®Google Scholar
• Du QQ, Shi W, Yu D, Yao KH. Epidemiology of non-vaccine serotypes of Streptococcus pneumoniae before and after universal administration of pneumococcal conjugate vaccines. Hum Vaccin Immunother. 2021;17:5628–37. doi:10.1080/21645515.2021.1985353.
   PubMed Web of Science ®Google Scholar
• Park DC, Kim SH, Yong D, Suh IB, Kim YR, Yi J, Song W, Song SA, Moon H-W, Lee HK, et al. Serotype distribution and antimicrobial resistance of invasive and noninvasive Streptococcus pneumoniae isolates in Korea between 2014 and 2016. Ann Lab Med. 2019;39:537–44. doi:10.3343/alm.2019.39.6.537.
   PubMed Web of Science ®Google Scholar
• Jung YH, Choe YJ, Lee CY, Jung SO, Lee DH, Yoo JI. Impact of national pneumococcal vaccination program on invasive pneumococcal diseases in South Korea. Sci Rep. 2022;12:15833. doi:10.1038/s41598-022-20363-9.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. VAXNEUVANCE™ (Pneumococcal 15-valent conjugate vaccine) prescribing information. 2021 [accessed 2022 Apr 19]. https://www.fda.gov/vaccines-blood-biologics/vaccines/vaxneuvance.
   Google Scholar
• Theilacker C, Fletcher MA, Jodar L, Gessner BD. PCV13 vaccination of adults against pneumococcal disease: what we have learned from the community-acquired pneumonia immunization trial in adults (CAPiTA). Microorganisms. 2022;10(1):127. doi:10.3390/microorganisms10010127.
   PubMed Web of Science ®Google Scholar
• Lo SW, Gladstone RA, van Tonder AJ, Lees JA, du Plessis M, Benisty R, Givon-Lavi N, Hawkins PA, Cornick JE, Kwambana-Adams B, et al. Pneumococcal lineages associated with serotype replacement and antibiotic resistance in childhood invasive pneumococcal disease in the post-PCV13 era: an international whole-genome sequencing study. Lancet Infect Dis. 2019;19(7):759–69. doi:10.1016/S1473-3099(19)30297-X.
   PubMed Web of Science ®Google Scholar
• Golden AR, Adam HJ, Gilmour MW, Baxter MR, Martin I, Nichol KA, Demczuk WHB, Hoban DJ, Zhanel GG. Assessment of multidrug resistance, clonality and virulence in non-PCV-13 streptococcus pneumoniae serotypes in Canada, 2011–13. J Antimicrob Chemother. 2015;70:1960–4. doi:10.1093/jac/dkv061.
   PubMed Web of Science ®Google Scholar
• Electronic Medicines Compendium. Vaxneuvance. 2022 [accessed 2023 Jun 6]. https://www.medicines.org.uk/emc/product/13754/smpc#gref.
   Google Scholar
• Clinicaltrials.gov. Safety and immunogenicity of V114 in healthy infants in South Korea (V114-036) (PNEU-PED-KOR). 2022 [accessed 2023 Jun 6] https://clinicaltrials.gov/ct2/show/NCT04633226?term=pneu-ped-kor&draw=2&rank=1.
   Google Scholar
• Korea Disease Control and Prevention Agency. National immunization program for children. [Accessed 2023 Jun 6]. https://www.kdca.go.kr/contents.es?mid=a30333000000.
   Google Scholar
• Nolan KM, Zhang Y, Antonello JM, Howlett AH, Bonhomme CJ, Greway R, Green T, de Gorguette d’Argoeuves P, Goldblatt D, Murphy RD, et al. Enhanced antipneumococcal antibody electrochemiluminescence assay: validation and bridging to the WHO reference ELISA. Bioanalysis. 2020;12(19):1363–75. doi:10.4155/bio-2020-0023.
   PubMed Web of Science ®Google Scholar
• Lupinacci R, Rupp R, Wittawatmongkol O, Jones J, Quinones J, Ulukol B, Dagan R, Richmond P, Stek JE, Romero L, et al. A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED). Vaccine. 2023;41(5):1142–52. doi:10.1016/j.vaccine.2022.12.054.
   PubMedGoogle Scholar
• Benfield T, Ramet M, Valentini P, Seppä I, Dagan R, Richmond P, Mercer S, Churchill C, Lupinacci R, McFetridge R, et al. Safety, tolerability, and immunogenicity of V114 pneumococcal vaccine compared with PCV13 in a 2+1 regimen in healthy infants: a phase III study (PNEU-PED-EU-2). Vaccine. 2023;41(15):2456–65. doi:10.1016/j.vaccine.2023.02.041.
   PubMed Web of Science ®Google Scholar
• Martinón-Torres F, Wysocki J, Szenborn L, Carmona-Martinez A, Poder A, Dagan R, Richmond P, Gilbert C, Trudel MC, Flores S, Lupinacci, R, et al., V114-025 PNEU-PED-EU-1 study group. A Phase 3, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1). Vaccine. 2023 May 16;41(21):3387–3398. doi:10.1016/j.vaccine.2023.04.036.
   Google Scholar
• Ishihara Y, Kuroki H, Hidaka H, Iwai K, Wan K, Shirakawa M, Sawata M. Safety and immunogenicity of a 15-valent pneumococcal conjugate vaccine in Japanese healthy infants: a phase I study (V114-028). Hum Vaccin Immunother. 2023;19:2180973. doi:10.1080/21645515.2023.2180973.
   PubMed Web of Science ®Google Scholar
• Banniettis N, Horn M, Sadarangani M, Patel SM, Greenberg D, Oberdorfer P, Klein NP, Rupp R, Dagan R, Richmond P, et al. Safety and tolerability of V114 pneumococcal vaccine in infants: a phase 3 study. Pediatrics. 2023;152(1). doi:10.1542/peds.2022-060428.
   PubMed Web of Science ®Google Scholar
• Choe YJ, Blatt DB, Lee HJ, Choi EH. Associations between geographic region and immune response variations to pneumococcal conjugate vaccines in clinical trials: a systematic review and meta-analysis. Int J Infect Dis. 2020;92:261–8. doi:10.1016/j.ijid.2019.12.021.
   PubMed Web of Science ®Google Scholar